Assessment | Who | When | |||||||
---|---|---|---|---|---|---|---|---|---|
Patient | Research assistants | RMO team | Screening | Randomisation | Week 2 | Week 4 | Week 8 | Week 12 | |
Case note review | x | x | |||||||
SCID | x | x | |||||||
Drug treatment history | x | x | x | x | x | x | x | ||
Medical history | x | x | |||||||
Physical exam | x | x | x | ||||||
Body weight and BMI | x | x | x | ||||||
BP and HR | x | x | x | x | x | x | x | ||
Lab screena | x | x | x | x | x | x | |||
Pregnancy screen (urine) | x | x | x | x | |||||
Inclusion criteria | x | x | |||||||
Exclusion criteria | x | x | |||||||
Withdrawal criteria | x | x | x | x | x | ||||
Consent | x | x | x | x | |||||
PANNS | x | x | x | x | x | x | |||
CGI | x | x | x | x | x | x | |||
GAF | x | x | x | ||||||
QOL | x | x | x | ||||||
Social function scale | x | x | x | ||||||
Cognitive assessments | x | x | x | ||||||
Antipsychotic side-effects | x | x | x | x | x | x | |||
Side-effects | |||||||||
Spontaneously reported adverse effects and | |||||||||
methotrexate toxicity check list | x | x | x | x | x | x | x | ||
Compliance monitoring | x | x | x | x | x |